A case report study has been reported the FGFR2 amplification in primary colorectal cancer, suggesting that a more in-depth insight of FGFR2 amplification in colorectal tumors could find a group of CRC patients that possibly benefit from FGFR tyrosine-kinase inhibitor therapy, since it has been shown that several FGFR TKIs, including AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line (Carter et al., 2017[8]). The gene discussed is FGFR2; the disease is colorectal cancer.